UNCY

MKT CAP:$157M

Unicycive Therapeutics, Inc.

Market Cap

$157M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$7.35+$1.55 (+26.72%)

Apr 23, 2026

Company Details

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and...

CEO

Shalabh K. Gupta

IPO Date

Jul 12, 2021

Website

www.unicycive.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$27M

EPS (Diluted)

-$1.67

Free Cash Flow

-$31M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 13, 2026

PENDING

FY 2025

Mar 30, 2026

$0EPS -$1.67

Q4 2025

Mar 30, 2026

$0EPS -$0.32

Q3 2025

Nov 12, 2025

$0EPS -$0.33

Q2 2025

Aug 14, 2025

$0EPS -$0.52

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$4M
Q2 22	$0	$0	-$4M
Q3 22	$951.0K	$951.0K	-$6M
Q4 22	$0	$0	-$5M
Q1 23	$675.0K	$675.0K	-$4M
Q2 23	$0	$0	-$4M
Q3 23	$0	$0	-$6M
Q4 23	$0	$0	-$6M
Q1 24	$0	-$284.0K	-$9M
Q2 24	$0	$0	-$7M
Q3 24	$0	$0	-$6M
Q4 24	$0	$0	-$9M
Q1 25	$0	$0	-$8M
Q2 25	$0	$0	-$7M
Q3 25	$0	$0	-$7M
Q4 25	$0	-$151.0K	-$7M

Valuation

Quarter	P/S	P/E
Q1 22	—	—
Q2 22	—	—
Q3 22	9.6x	—
Q4 22	7.2x	—
Q1 23	20.9x	—
Q2 23	23.1x	—
Q3 23	47.4x	—
Q4 23	48.1x	—
Q1 24	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	—	—
Q1 25	—	—
Q2 25	—	—
Q3 25	—	—
Q4 25	—	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$3M	-$3M
Q2 22	-$3M	-$3M
Q3 22	-$4M	-$4M
Q4 22	-$6M	-$6M
Q1 23	-$4M	-$4M
Q2 23	-$6M	-$6M
Q3 23	-$4M	-$4M
Q4 23	-$4M	-$4M
Q1 24	-$6M	-$6M
Q2 24	-$6M	-$6M
Q3 24	-$9M	-$9M
Q4 24	-$7M	-$7M
Q1 25	-$9M	-$9M
Q2 25	-$8M	-$8M
Q3 25	-$6M	-$6M
Q4 25	-$8M	-$8M

Capital Expenditures

Quarter	CapEx
Q1 22	$2.0K
Q2 22	$0
Q3 22	$0
Q4 22	$2.0K
Q1 23	$0
Q2 23	$12.0K
Q3 23	$0
Q4 23	$0
Q1 24	$6.0K
Q2 24	$20.0K
Q3 24	$24.0K
Q4 24	$22.0K
Q1 25	$16.0K
Q2 25	$6.0K
Q3 25	$2.0K
Q4 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+383.9%
Q2 22	—	+366.8%
Q3 22	—	+38.0%
Q4 22	—	+93.5%
Q1 23	—	+37.9%
Q2 23	—	+18.9%
Q3 23	-100.0%	-8.7%
Q4 23	—	+18.6%
Q1 24	-100.0%	+88.7%
Q2 24	—	+71.2%
Q3 24	—	+5.3%
Q4 24	—	+46.7%
Q1 25	—	-13.2%
Q2 25	—	-5.9%
Q3 25	—	+17.5%
Q4 25	—	-22.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$290.0K	—
Q2 22	$294.0K	—
Q3 22	$266.0K	28.0%
Q4 22	$197.0K	—
Q1 23	$144.0K	21.3%
Q2 23	$144.0K	—
Q3 23	$929.0K	—
Q4 23	$550.0K	—
Q1 24	$522.0K	—
Q2 24	$641.0K	—
Q3 24	$605.0K	—
Q4 24	$582.0K	—
Q1 25	$563.0K	—
Q2 25	$571.0K	—
Q3 25	$0	—
Q4 25	$777.0K	—

OpEx Breakdown

Quarter	R&D	G&A
Q1 22	$2M	$2M
Q2 22	$2M	$2M
Q3 22	$5M	$2M
Q4 22	$4M	$1M
Q1 23	$3M	$2M
Q2 23	$2M	$2M
Q3 23	$3M	$3M
Q4 23	$4M	$2M
Q1 24	$7M	$2M
Q2 24	$5M	$3M
Q3 24	$3M	$3M
Q4 24	$5M	$4M
Q1 25	$2M	$6M
Q2 25	$2M	$5M
Q3 25	$3M	$4M
Q4 25	$2M	$5M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$14M	$0	$14M
Q2 22	$11M	$0	$11M
Q3 22	$7M	$0	$7M
Q4 22	$455.0K	$0	$455.0K
Q1 23	$24M	$0	$24M
Q2 23	$19M	$0	$19M
Q3 23	$14M	$0	$14M
Q4 23	$10M	$0	$10M
Q1 24	$49M	$0	$49M
Q2 24	$42M	$0	$42M
Q3 24	$32M	$0	$32M
Q4 24	$26M	$0	$26M
Q1 25	$20M	$0	$20M
Q2 25	$22M	$0	$22M
Q3 25	$43M	$0	$43M
Q4 25	$29M	$12M	$41M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	2M	+6.0%	-82.5%
Q2 22	2M	+0.1%	+7.5%
Q3 22	2M	+0.2%	-89.4%
Q4 22	2M	+1.1%	+7.5%
Q1 23	2M	+0.0%	+1.4%
Q2 23	2M	+0.0%	+1.4%
Q3 23	3M	+114.2%	+116.7%
Q4 23	3M	+6.5%	+128.2%
Q1 24	3M	+0.5%	+129.2%
Q2 24	9M	+169.4%	+517.4%
Q3 24	9M	-5.4%	+172.6%
Q4 24	7M	-24.7%	+92.7%
Q1 25	12M	+84.9%	+254.7%
Q2 25	12M	-0.7%	+30.8%
Q3 25	18M	+46.8%	+103.1%
Q4 25	159M	+779.4%	+2271.7%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	9
Q2 22	$0	9
Q3 22	$105.7K	9
Q4 22	$0	12
Q1 23	$56.3K	12
Q2 23	$0	12
Q3 23	$0	12
Q4 23	$0	14
Q1 24	$0	14
Q2 24	$0	14
Q3 24	$0	14
Q4 24	$0	22
Q1 25	$0	22
Q2 25	$0	22
Q3 25	$0	22
Q4 25	$0	21

Revenue / Employee